This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Peripheral Nerves and Autonomic Nervous System말초신경 및 자율신경계통의 악성신생물 (말초신경암)

Classification codesC47 (ICD-10) — C47.0 head and neck, C47.1 upper limb, C47.2 lower limb, C47.3 trunk, C47.4 abdomen, C47.5 pelvis, C47.8 overlapping lesion, C47.9 unspecified
SynonymsMalignant peripheral nerve sheath tumor (MPNST), Neurofibrosarcoma, Malignant Schwannoma, Neurosarcoma, malignant epineurioma
Adult onsetNot low — NF1-associated type in the 20s–50s, sporadic type in the 40s–60s; pediatric MPNST is almost always NF1-associated
Special Copayment ReductionV193 — 5 years from the date of cancer patient registration, copayment 5%
1. HistoryDescribed by von Recklinghausen (1882), the name MPNST formalized by WHO (1986), selumetinib FDA approval (2020)
2. CausesNF1-associated (50%), radiation-induced (10%), sporadic (40%); PHEO/PGL hereditary in 40%
3. GeneticsNF1/CDKN2A/PRC2 (EED, SUZ12)/TP53; loss of H3K27me3 as a diagnostic biomarker for MPNST
4. Epidemiology3–10% of soft tissue sarcomas; lifetime risk in NF1 patients 8–13%; occurs mainly in the limbs and trunk
5. PathophysiologyMultistep malignant transformation from neurofibroma to MPNST; RAS-MAPK hyperactivation; PRC2 loss
6. SymptomsRapidly enlarging mass, worsening pain, neurologic deficits; triad of paroxysmal hypertension in PHEO
7. SignsCafé-au-lait macules, plexiform neurofibromas, Lisch nodules, motor and sensory deficits
8. ScreeningWhole-body MRI every 2–3 years for high-risk NF1, FDG-PET/CT (SUVmax>3.5), gene panel
9. DiagnosisMRI/PET-CT/core needle biopsy/IHC (loss of H3K27me3)/NGS molecular testing
10. TreatmentWide resection (R0), radiation 60–66 Gy, doxorubicin ± ifosfamide, selumetinib
11. Prognosis5-year survival 20–50%; poorer in NF1-associated type; 50–67% with R0 resection
12. PreventionNF1 genetic counseling and family cascade testing, minimizing radiation exposure, regular multidisciplinary follow-up
13. ReferencesKey references

1. History

The history of malignant neoplasms of the peripheral nerves and autonomic nervous system, particularly Malignant Peripheral Nerve Sheath Tumor (MPNST), goes back to the 19th-century German pathologist Friedrich von Recklinghausen. In 1882 he systematically described neurofibromatosis type 1 (NF1) and was the first to recognize that this disease is closely associated with tumors of neural origin. At the time these tumors were called Neurofibrosarcoma, and because they were thought to originate from Schwann cells, the name Malignant Schwannoma was also used interchangeably. NF1 was long known as von Recklinghausen's disease.

With the development of histopathology in the early 20th century, various malignant tumors arising from the epineurium, perineurium and endoneurium were classified. In 1986 the World Health Organization (WHO) unified this group of tumors and formalized the name MPNST, and through the WHO classification revisions of 2013 and 2020, earlier names such as neurofibrosarcoma, malignant schwannoma and neurosarcoma were consolidated into MPNST. The 2020 WHO Classification of Soft Tissue and Bone Tumours (5th edition) subdivided MPNST into Schwann cell, perineurial cell and mixed types.

Among malignant tumors of the autonomic nervous system, Neuroblastoma was first described by Rudolf Virchow in 1865, and in 1910 James Homer Wright classified it as a tumor derived from the sympathetic nervous system. The Homer Wright rosette, named after him, is known as a characteristic pathologic finding of neuroblastoma. In the late 20th century, molecular understanding advanced rapidly with discoveries such as MYCN amplification (discovered in 1983) and ALK mutations.

In the history of treatment, the FDA approval of selumetinib (brand name Koselugo) in 2020 was a landmark turning point. This MEK1/2 inhibitor was recognized as the first effective systemic therapy for pediatric patients with NF1-related plexiform neurofibromas, and in Korea National Health Insurance coverage for pediatric NF1 patients began in January 2024. In Korea, major institutions such as the Severance Hospital Rare Disease Center, Seoul National University Hospital, Samsung Medical Center and Chungbuk National University Hospital operate specialized multidisciplinary clinics for NF1 and MPNST.

2. Causes

The causes of MPNST and malignant tumors of the peripheral and autonomic nervous systems are broadly divided into genetic predisposition and environmental factors, and about half of all MPNSTs are associated with NF1.

Neurofibromatosis type 1 (NF1)

NF1 is the most important risk factor for MPNST, with a lifetime risk of 8–13% in NF1 patients. NF1 is an autosomal dominant genetic disorder caused by pathogenic variants of the NF1 gene located on chromosome 17 (17q11.2), occurring in about 1 in 3,000–4,000 people. The NF1 gene product, neurofibromin, functions as a RAS-GTPase–activating protein (RAS-GAP) and downregulates RAS signaling. More than 5,000 pathogenic variants of the gene have been reported, and the risk of MPNST is higher especially in patients with a large deletion.

Radiation exposure

Radiation-induced MPNST can arise in areas previously treated with radiotherapy, with a mean latency of 10–20 years. Radiation-induced MPNST accounts for about 10% of all MPNSTs, and cases have been reported after radiotherapy for breast cancer, lymphoma, cervical cancer and others.

Sporadic cases and others

About 40–50% of all MPNSTs arise sporadically without NF1 or radiation exposure. Somatic NF1 mutations, CDKN2A deletion, TP53 mutations and loss of function of the PRC2 complex are jointly involved. In malignant pheochromocytoma/paraganglioma (PHEO/PGL), germline mutations in related genes such as SDHA/B/C/D, VHL, RET, NF1, TMEM127, MAX are found in about 30–40%. Most neuroblastomas are sporadic, but germline mutations in the ALK, PHOX2B genes are associated with familial neuroblastoma.

3. Genetics

The molecular pathogenesis of MPNST is complex, involving three main genetic pathways. Advances in next-generation sequencing (NGS) have characterized the genomic features of MPNST in detail.

NF1/RAS signaling pathway

A heterozygous germline mutation of the NF1 gene (17q11.2) followed by somatic loss of the second allele (LOH) is the key molecular event in NF1-associated MPNST. RAS-GTP hyperactivation due to NF1 loss promotes cell proliferation and survival through the MAPK (MEK-ERK) and PI3K/AKT/mTOR pathways. This is the therapeutic rationale for the MEK inhibitor selumetinib. In neuroblastoma, ALK activating mutations/amplification likewise activate the RAS-MAPK pathway and are targets of ALK inhibitors such as crizotinib and lorlatinib.

Cell-cycle dysregulation: CDKN2A

CDKN2A (p16/p14ARF) deletion is observed in about 50–70% of MPNSTs and is especially common in high-grade tumors. Loss of p16 releases CDK4/6 inhibition and accelerates the G1-S cell-cycle transition, and loss of p14ARF promotes p53 degradation via MDM2, suppressing apoptosis. In malignant pheochromocytoma, SDHB mutations are associated with metastatic disease and poor prognosis.

Epigenetic abnormalities: PRC2 complex

Loss-of-function mutations of EED or SUZ12, components of the PRC2 complex (Polycomb Repressive Complex 2), occur in about 50–80% of MPNSTs. This leads to loss of trimethylation of lysine 27 on histone H3 (H3K27me3), and immunohistochemical loss of H3K27me3 is an important diagnostic biomarker distinguishing MPNST from benign neurofibroma and other soft tissue tumors (sensitivity about 50–80%, specificity >90%). In neuroblastoma, MYCN amplification (a marker of poor prognosis in the high-risk group) and PHOX2B mutations (familial neuroblastoma associated with congenital central hypoventilation syndrome) are important. Pharmacogenomically, response to MEK inhibitors (selumetinib) is related to the activation status of the RAS/MAPK pathway, and clinical molecular profiling is used in treatment decisions.

4. General epidemiology

MPNST is a rare tumor accounting for about 3–10% of all soft tissue sarcomas, with an annual incidence of less than about 1 per million population. In the United States, about 500–1,000 new cases are estimated to be diagnosed each year. Worldwide, about 50% are NF1-associated, about 10% radiation-induced and about 40% sporadic.

The median age at onset is about 28 years for the NF1-associated type and about 44 years for the sporadic type, so the NF1-associated type occurs at a younger age. Pediatric MPNST is almost always associated with NF1. There is no clear sex difference. In Korea, soft tissue sarcomas including MPNST account for less than about 1% of all malignancies and are classified as rare diseases. The number of NF1 patients in Korea is estimated at about 1 per 3,000–4,000 population. Neuroblastoma, a malignant tumor of the autonomic nervous system, accounts for about 8–10% of pediatric solid tumors worldwide and also accounts for a considerable share of childhood cancers in Korea. The main sites of occurrence are, in order, the limbs (30–40%), trunk (20–30%), head and neck (10–15%) and retroperitoneum (10–15%).

5. Pathophysiology

The pathogenesis of MPNST is understood as a process of multistep malignant transformation from normal Schwann cells or neurofibroma to MPNST.

Step 1: in normal Schwann cells, germline heterozygous loss of NF1 causes partial activation of RAS, and a plexiform neurofibroma forms through non-cell-autonomous interactions with mast cells, fibroblasts and other cells in the tumor microenvironment. Already at this stage, a somatic mutation or LOH of the second NF1 allele in NF1-heterozygous Schwann cells is required.

Step 2: in Schwann cells within the neurofibroma, CDKN2A deletion simultaneously blocks the p16/Rb pathway and the p14ARF/MDM2/p53 pathway, and loss of function of the PRC2 (EED, SUZ12) complex causes loss of H3K27me3, collapsing epigenetic repressive function. As these secondary genetic events accumulate, the tumor evolves through atypical neurofibroma to low-grade and then high-grade MPNST. Sustained hyperactivation of RAS-MAPK signaling and immune evasion mechanisms in the tumor microenvironment (such as PD-L1 expression) accelerate progression. In radiation-induced MPNST, radiation-induced DNA double-strand breaks and genomic instability are the main mechanisms.

6. Symptoms

The clinical symptoms of MPNST vary with the tumor's location, size and nerve involvement, and the presence of NF1 influences the clinical picture.

Local tumor symptoms

Systemic and metastatic symptoms

Symptoms of autonomic nervous system tumors

Malignant pheochromocytoma is characterized by the triad of paroxysmal hypertension, headache, sweating and palpitations due to excessive catecholamine secretion. In malignant paraganglioma, chest pain, dysphagia and superior vena cava syndrome due to a mediastinal mass may occur. In neuroblastoma (children), an abdominal mass, periorbital ecchymosis (raccoon eyes), spinal cord compression (lower limb weakness, bladder and bowel dysfunction) and Horner syndrome occur.

7. Signs

The main signs observed on physical examination and clinical evaluation vary with tumor type and site.

NF1-related physical findings

Signs related to MPNST tumors

Signs related to autonomic nervous system tumors

8. Screening

No standard screening program for MPNST in the general population has been established. In NF1 patients, a high-risk group, systematic follow-up is key.

Monitoring of high-risk NF1 patients

Genetic counseling and genetic testing

When NF1 is suspected or confirmed, NF1 gene variant testing (NGS panel) is performed. For malignant PHEO/PGL, gene panel testing including SDHA/B/C/D, VHL, RET, NF1, TMEM127, MAX is recommended for all patients. In Korea, after NF1 is confirmed, referral to a clinical genetics specialist and cascade testing of family members are important.

9. Diagnosis

The diagnosis of MPNST is made by a three-pronged approach of clinical features, imaging findings and histopathologic confirmation, and multidisciplinary evaluation at a specialized soft tissue sarcoma center is recommended.

Imaging tests

Histopathological diagnosis

Staging

Staging follows the AJCC staging system for soft tissue sarcoma (8th edition), classifying tumors as stage I–IV by tumor size (5 cm cutoff), depth (superficial/deep), FNCLCC tumor grade (grades 1–3), lymph node metastasis and distant metastasis.

10. Treatment

The cornerstone of MPNST treatment is complete surgical resection (R0 resection), and multidisciplinary treatment planning at a specialized soft tissue sarcoma center improves prognosis.

Surgical treatment

Wide resection aims for negative margins (R0), and margin status is the single most important prognostic factor. For limb MPNST, limb-salvage surgery is considered first, combined with preoperative or postoperative radiotherapy. Re-resection is actively considered even for recurrent resectable tumors. Reconstruction with nerve grafting may be considered.

Radiation therapy

Adjuvant radiotherapy (total 60–66 Gy) is given for high-grade MPNST and after resection with positive margins (R1/R2) or close margins. For unresectable tumors, palliative radiotherapy alone or combined with chemotherapy is considered. Preoperative radiotherapy (50 Gy) can be used to reduce the extent of surgery and improve resectability.

Chemotherapy

The standard first-line systemic therapy for MPNST is doxorubicin alone (75 mg/m² every 3 weeks) or doxorubicin + ifosfamide combination therapy. Response rates are about 25% for monotherapy and about 30–35% for combination therapy. Gemcitabine + docetaxel, eribulin, pazopanib and others are considered as second-line salvage therapy. Preoperative neoadjuvant chemotherapy is used to shrink the tumor and improve resectability.

Targeted therapy and new drugs

Selumetinib (Koselugo) received FDA approval and Korean National Health Insurance coverage (January 2024) for the treatment of NF1-associated plexiform neurofibroma (unresectable, children aged 2 years and older). It blocks the RAS-MAPK pathway through MEK1/2 inhibition. In malignant PHEO/PGL, 131I-MIBG therapy (or 177Lu-DOTATATE), sunitinib, cabozantinib and others are used. In neuroblastoma, depending on risk group, surgery, chemotherapy, radiotherapy, immunotherapy (dinutuximab), 131I-MIBG therapy and ALK inhibitors (crizotinib) are applied.

11. Prognosis

MPNST is a group of tumors with a poor prognosis among soft tissue sarcomas, with a 5-year survival rate below 50% in most studies.

Prognostic factorsDetails
Overall 5-year survival rate20–50% (varies with stage, margins and tumor grade)
NF1-associated typePoorer than sporadic; 5-year disease-free survival 34–60%
When complete R0 resection is achieved5-year survival improves to 50–67%
High grade (FNCLCC grade 3)High rate of distant metastasis, 5-year survival 15–35%
Metastatic diseaseMedian overall survival about 12 months
Radiation-induced MPNSTPoor prognosis similar to the NF1-associated type
Head and neck or retroperitoneal locationPoor prognosis because complete resection is difficult

Most recurrences occur within 2 years after treatment, and the lung is the most common site of distant metastasis (about 60–70%). In neuroblastoma, MYCN amplification and high-grade histology suggest a poor prognosis, but low-risk infantile neuroblastoma (stage 4S) can regress spontaneously and has a very good prognosis (5-year survival >90%).

12. Prevention

No specific preventive measures have yet been established for malignant tumors of the peripheral and autonomic nervous systems, including MPNST, but the following approaches are recommended for high-risk groups.

Genetic counseling and family cascade testing

Minimizing radiation exposure and regular follow-up

13. References

  1. Evans DG, et al. Malignant Peripheral Nerve Sheath Tumours in Neurofibromatosis 1. J Med Genet. 2002;39(5):311-314.
  2. Genetics of human malignant peripheral nerve sheath tumors. Acta Neuropathologica. 2020. PMC7317054.
  3. Survival and NF1 Analysis in a Cohort of Orthopedics Patients with MPNST. Sarcoma. 2021; PMC8505086.
  4. Malignant Peripheral Nerve Sheath Tumor (MPNST). Cleveland Clinic Health Library. 2024.
  5. Prognostic Significance of IHC Markers and Genetic Alterations in MPNST. Systematic Review. PMC7783392. 2021.
  6. Role of Pre-Operative Biopsy in MPNST: A Review. PMC12473013. 2025.
  7. WHO Classification of Soft Tissue and Bone Tumours. 5th ed. IARC Press. 2020.
  8. FDA Approval of Selumetinib (Koselugo) for NF1 pediatric patients. 2020.
  9. Severance Hospital Rare Disease Center. Neurofibromatosis Type 1 Clinic. 2024.
  10. National Cancer Information Center. Cancer statistics in Korea 2023. 2025.